Activity of glycopeptides against vancomycin-resistant gram-positive bacteria
about
Solid- and solution-phase synthesis of vancomycin and vancomycin analogues with activity against vancomycin-resistant bacteria.Vancomycin-resistant enterococci.Modification of peptidoglycan precursors is a common feature of the low-level vancomycin-resistant VANB-type Enterococcus D366 and of the naturally glycopeptide-resistant species Lactobacillus casei, Pediococcus pentosaceus, Leuconostoc mesenteroideActivities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.In vitro activity of the trinem sanfetrinem (GV104326) against gram-positive organisms.In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptidePhenotypic and genotypic heterogeneity of glycopeptide resistance determinants in gram-positive bacteria.Resistance of enterococci to glycopeptides.Current perspectives on glycopeptide resistance.In vitro activities of three semisynthetic amide derivatives of teicoplanin, MDL 62208, MDL 62211, and MDL 62873In vitro activity of decaplanin (M86-1410), a new glycopeptide antibiotic.Brain abscess due to Wolinella recta and Streptococcus intermedius.Resistance to vancomycin and teicoplanin: an emerging clinical problem.Screening and treatment of infections caused by resistant enterococci.Antibacterial activities and modes of action of vancomycin and related glycopeptides.Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.Genetics and mechanisms of glycopeptide resistance in enterococci.Vancomycin-resistant Leuconostoc mesenteroides and Lactobacillus casei synthesize cytoplasmic peptidoglycan precursors that terminate in lactateEnterococcus, an emerging pathogen.D-Alanyl-D-lactate and D-alanyl-D-alanine synthesis by D-alanyl-D-alanine ligase from vancomycin-resistant Leuconostoc mesenteroides. Effects of a phenylalanine 261 to tyrosine mutation.Isolation of vancomycin-resistant lactobacilli from three neutropenic patients with pneumonia.
P2860
Q30725913-00EDB853-7D5B-4B69-9672-9E21FE070694Q33975592-B25D1737-271C-4389-BA2E-A58EACFA3D9DQ34060614-5A04E203-5797-482B-8CE9-993DB953DAC8Q35120483-C0E08D69-49B5-4AB6-A379-63F01F6084D6Q35126947-F6CE1352-030F-4D32-8E3E-93FB66A6FD90Q35138478-B96DE7BC-62A4-4D88-8E57-353B1BA51CB6Q35276250-20670F61-67C8-473A-90A8-168F4FE51B02Q35284014-05C79142-5DD5-400C-9881-7210423AB4F4Q35368590-1BD7DB1F-41CC-4FF9-808B-2224EDA1BF60Q35825738-4EB887B1-1E3B-4470-9901-99BCEAE00E39Q35846789-9933498A-BCE3-4C78-9A1E-F661C15DAABAQ35893055-0C8C93F7-C458-4BA7-99EF-B9F8A2FCC50BQ36636341-976A825F-B9F4-4D9E-A896-2625FF75ECDBQ37711795-54837315-C01B-4331-A44B-4E5C72A4F6FEQ37778683-11E6B7E9-B86D-463F-BED2-D38E1F1EF4EDQ38233471-5667A15E-33B3-4218-A750-B44DB322F4E0Q39866365-E61F20A5-FFAA-4B18-BAD1-1C005648B0E5Q39930098-A910D151-45F9-4157-8950-0119C2A90C35Q40785841-FDE2F2C0-3DFD-469B-8A6C-85D6B7378DA1Q48051329-F0135349-68C2-4B1C-B004-414B18F0F8D5Q54234943-8555750D-9F30-40D8-A847-79FB2CEA1142
P2860
Activity of glycopeptides against vancomycin-resistant gram-positive bacteria
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Activity of glycopeptides against vancomycin-resistant gram-positive bacteria
@en
Activity of glycopeptides against vancomycin-resistant gram-positive bacteria.
@nl
type
label
Activity of glycopeptides against vancomycin-resistant gram-positive bacteria
@en
Activity of glycopeptides against vancomycin-resistant gram-positive bacteria.
@nl
prefLabel
Activity of glycopeptides against vancomycin-resistant gram-positive bacteria
@en
Activity of glycopeptides against vancomycin-resistant gram-positive bacteria.
@nl
P2093
P2860
P356
P1476
Activity of glycopeptides against vancomycin-resistant gram-positive bacteria
@en
P2093
P2860
P304
P356
10.1128/AAC.33.9.1477
P407
P577
1989-09-01T00:00:00Z